PLUS THERAPEUTICS, INC.
PSTVPlus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™ (rhenium Re-186 obisbemeda), is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PSTV Earnings Report
EPS Est: $-0.96 | FQ end 2026-06
How PSTV's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rhenium Liposome Treatment | Phase 2 | Glioma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PLUS THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PLUS THERAPEUTICS, INC.'s (PSTV) pipeline across Phase 2. Its lead program is Rhenium Liposome Treatment (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PLUS THERAPEUTICS, INC.'s next FDA catalyst?→
PLUS THERAPEUTICS, INC.'s (PSTV) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PSTV biotech catalysts?→
Add PSTV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PLUS THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.